Molecular structure of Pergolide Mesylate, CAS Number: 66104-23-2
Pergolide Mesylate (CAS 66104-23-2)
Application:
Pergolide Mesylate is A dopaminergic agonist
CAS Number:
66104-23-2
Molecular Weight:
410.60
Molecular Formula:
C20H30N2O3S2
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
An antiparkinsonian agent. A dopaminergic agonist that also decrease plasma prolactin concentrations.
Pergolide Mesylate (CAS 66104-23-2) References
- Developmental toxicity of the dopamine agonist pergolide mesylate in CD-1 mice. II: Perinatal and postnatal exposure. | Buelke-Sam, J., et al. 1991. Neurotoxicol Teratol. 13: 297-306. PMID: 1886539
- Effects of compounding and storage conditions on stability of pergolide mesylate. | Davis, JL., et al. 2009. J Am Vet Med Assoc. 234: 385-9. PMID: 19210262
- Effects of oral pergolide mesylate on nociceptive spinal cord reflexes in rats. | Shannon, HE., et al. 1991. Life Sci. 48: 2243-8. PMID: 2046457
- Single-dose oral pharmacokinetics of pergolide mesylate in healthy adult mares. | Gehring, R., et al. 2010. Vet Ther. 11: E1-8. PMID: 20949429
- Effects of pergolide mesylate on transduction efficiency of PEP-1-catalase protein. | Sohn, EJ., et al. 2011. Biochem Biophys Res Commun. 406: 336-40. PMID: 21324306
- Multitemperature stability and degradation characteristics of pergolide mesylate oral liquid. | Shank, BR. and Ofner, CM. 2010. J Pharm Pract. 23: 570-4. PMID: 21507864
- Stability of pergolide mesylate oral liquid at room temerature. | Shank, BR. and Ofner, CM. 2009. Int J Pharm Compd. 13: 254-8. PMID: 23966481
- Pharmacokinetics of pergolide after intravenous administration to horses. | Rendle, DI., et al. 2015. Am J Vet Res. 76: 155-60. PMID: 25629913
- Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction. | McFarlane, D., et al. 2017. J Vet Pharmacol Ther. 40: 158-164. PMID: 27301465
- The effect of pergolide mesylate on adrenocorticotrophic hormone responses to exogenous thyrotropin releasing hormone in horses. | Durham, AE. 2022. Vet J. 285: 105831. PMID: 35477010
- Pharmacokinetic properties of pergolide mesylate following single and multiple-dose administration in donkeys (Equus asinus). | Xue, C., et al. 2022. Equine Vet J.. PMID: 36572900
- Behavioral effects of pergolide mesylate on food intake and body weight. | Greene, SB., et al. 1985. Pharmacol Biochem Behav. 23: 161-7. PMID: 4059302
- VMN lesion deficits in lordosis: partial reversal with pergolide mesylate. | Mathews, D., et al. 1983. Physiol Behav. 31: 745-8. PMID: 6665063
- Reproductive and developmental toxicity of the dopamine agonist pergolide mesylate in mice. | Hoyt, JA., et al. 1994. Arzneimittelforschung. 44: 1177-83. PMID: 7848327
Activator of:
D1DR, D2DR, and D3DR.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Pergolide Mesylate, 2.5 mg | sc-212538 | 2.5 mg | $380.00 |